Evaluation of the sirna pf-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (monet study)

Ophthalmology, 06/12/2012

In this, early, underpowered study evaluating treatments for neovascular age–related macular degeneration (AMD), the combination of PF with ranibizumab led to an average gain in best–corrected visual acuity (BCVA) that was more than with ranibizumab monotherapy. No safety concerns were identified.

Print Article Summary Cat 2 CME Report